Induction of CYP3A activity by dexamethasone may not be strong, even at high doses: insights from a case of tacrolimus co-administration
Abstract Background Dexamethasone (DEX) induces CYP3A activity in a concentration-dependent manner. However, no study has examined changes in the blood concentration of CYP3A substrate drugs when DEX is administered at high doses. Herein, we present a case in which tacrolimus (TAC), a typical CYP3A...
Main Authors: | Yoshiyuki Ohno, Toyohito Oriyama, Akira Honda, Mineo Kurokawa, Tappei Takada |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-12-01
|
Series: | Journal of Pharmaceutical Health Care and Sciences |
Subjects: | |
Online Access: | https://doi.org/10.1186/s40780-023-00310-0 |
Similar Items
-
Comparison of the safety and efficacy of topical Tacrolimus (0.03%) versus dexamethasone (0.05%) for subepithelial infiltrates after adenoviral conjunctivitis
by: Rahul Bhargava, et al.
Published: (2019-01-01) -
Frequency of CYP3A5 Genetic Polymorphisms and Tacrolimus Pharmacokinetics in Pediatric Liver Transplantation
by: Jefferson Antonio Buendía, et al.
Published: (2020-09-01) -
CYP3A5 polymorphisms in renal transplant recipients: influence on tacrolimus treatment
by: Chen L, et al.
Published: (2018-03-01) -
Pharmacogenomic Analysis of CYP3A5*3 and Tacrolimus Trough Concentrations in Vietnamese Renal Transplant Outcomes
by: Nguyen TVA, et al.
Published: (2024-02-01) -
Case report and literature review: management of Paxlovid (nirmatrelvir/ritonavir)-induced acute tacrolimus toxicity in a patient with systemic lupus erythematosus
by: Chenxiao Jiang, et al.
Published: (2024-06-01)